single5MG
LL-37
5MG Protocol
LL-37 5MG
Injection Freq.
Inject once daily
Cycle Sched.
8–12 weeks; optional extension to 16 weeks
Reconstitution
3.0 mL BAC water
Broad-spectrum antimicrobial activity via microbial-membrane disruption
Immune-modulating effects in sepsis models (reduced bacterial burden/mortality signals)
Accelerated wound-healing signals in topical ulcer studies (venous leg ulcers
diabetic foot ulcers)
Generally well tolerated in described contexts
1
Reconstitution Requirements
- 3.0 mL BAC water
| Step | Week Range | Dose | Units |
|---|---|---|---|
| 2 | Weeks 2–2 | 100 µg | 6 |
| 3 | Weeks 3–3 | 150 µg | 9 |
| 1 | Weeks 1–1 | 50 µg | 3 |
| 4 | Weeks 4–4 | 200 µg | 12 |
| 5 | Weeks 5–5 | 250 µg | 15 |
| 6 | Weeks 6–6 | 300 µg | 18 |
| 7 | Weeks 7–7 | 350 µg | 21 |
| 8 | Weeks 8–8 | 400 µg | 24 |
Inject once daily
8–12 weeks; optional extension to 16 weeks
LL-37 is presented as an endogenous antimicrobial peptide (cathelicidin) with both direct microbe-killing activity and ‘host-directed’ immune effects. The protocol explains that LL-37’s amphipathic, positively charged α-helical structure allows it to preferentially bind to negatively charged microbial membranes and disrupt them, contributing to broad-spectrum antimicrobial action. Beyond membrane disruption, the page emphasizes immune modulation: in sepsis models, LL-37 was associated with neutrophil release of microvesicles enriched with antimicrobial proteins, lowering bacterial burden and improving survival. LL-37 is also described as binding bacterial lipopolysaccharide (LPS) and blocking LPS interaction with CD14/TLR4, which can reduce endotoxin-triggered TNF release and limit neutrophil apoptosis. Together, the mechanism is framed as a combination of direct antimicrobial membrane effects plus dampening of excessive endotoxin-driven inflammation—features that help explain reported interest in infection control and wound-healing contexts.
Mild injection-site reactions (redness/itching)
- Use aseptic technique: wipe vial stopper with alcohol; use new sterile syringe/needle
- Add diluent slowly down the vial wall to minimize foaming
- Gently swirl/roll until fully dissolved (do not shake)
- Label vial with reconstitution date and concentration; protect from light
- Refrigerate after reconstitution (commonly 2–8 °C) unless protocol states otherwise
- Avoid repeated freeze–thaw cycles
- Bacteriostatic Water for Injection contains benzyl alcohol preservative (multi-dose); follow protocol for beyond-use (many peptide protocols use ~28 days after mixing)
- Avoid benzyl-alcohol-containing diluents in neonates/infants (safety warning for benzyl alcohol)